Esteva, F. J.
Baranau, Y. V.
Baryash, V.
Manikhas, A.
Moiseyenko, V.
Dzagnidze, G.
Zhavrid, E.
Boliukh, D.
Stroyakovskiy, D.
Pikiel, J.
Eniu, A. E.
Li, R. K.
Rusyn, A. V.
Tiangco, B.
Lee, S. J.
Lee, S. Young
Yu, S. Y.
Stebbing, J.
Funding for this research was provided by:
Celltrion, Inc
Article History
Received: 12 July 2019
Accepted: 30 July 2019
First Online: 19 August 2019
Compliance with ethical standards
:
: FJE has received personal fees from Celltrion during the conduct of this study and personal fees from Celltrion, Genentech/Roche, Novartis, and Pfizer outside of the submitted work. YB, VB, and AE have received grants from Celltrion during the conduct of this study. YB has also received non-financial support from Roche and Pfizer outside of the submitted work, and personal fees from Roche outside of the submitted work. AE has also received grants from Roche during the conduct of this study and grants from AstraZeneca and Pfizer outside of the submitted work. SJL, SYL, and SYY are employees of CELLTRION, Inc. In 2018 - present Professor Stebbing, the Editor-in-Chief of Oncogene sat on scientific advisory boards for Celltrion, Singapore Biotech, Vor Biopharma, TLC Biopharmaceuticals and Benevolent AI, has consulted with Lansdowne partners, Vitruvian and Social Impact Capital and he Chairs the Board of Directors for BB Biotech Healthcare Trust and Xerion Healthcare. AM, VM, GD, EZ, DB, DS, JP, RKL, AR, and BT have nothing to disclose.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.